Illumina CEO On $50 Genomes: 'I'm Not Super Concerned' As He Pitches AI Datasets Over Cheap Sequencing
Jacob Thaysen says the Billion Cell Atlas is over halfway done and that AI buyers want data, not just sequencing.
Illumina CEO Jacob Thaysen brushed off a challenge from a Stifel analyst about genomes priced near $50, telling analysts on the company's third-quarter earnings call Thursday, "I'm not super concerned about what others are doing right now." Thaysen argued that AI customers are buying datasets, and that the company's third-quarter results are only part of the pitch.
Why price per genome is the wrong yardstick
The Stifel analyst asked whether Illumina would need to revisit its pricing to win large AI and virtual-cell projects, given talk of genomes falling toward $50. Thaysen said AI models go "way beyond what a whole genome pricing" implies, and that the opportunity spans the genome, transcriptome, methylome and proteome, across bulk, single-cell and spatial work.
He added: "There's no other company in this industry that have the broad portfolio and also have the ability to create those data sets." He also said Illumina is comfortable with price elasticity, meaning how demand responds to price, and can address any opportunity it needs to.
On a separate question, Thaysen said individual labs' small datasets are noisy, and that models trained on them often predict where the data came from rather than the underlying biology. That, he said, is why customers are asking Illumina to generate large, standardized, reproducible datasets.
The Billion Cell Atlas and BioInsight
Thaysen said the Billion Cell Atlas, introduced early in 2026, is now over halfway complete. GSK is the latest drugmaker to join its consortium, and other companies are showing growing interest in access to the finished dataset. Partners contribute input on the proprietary dataset.
Illumina also launched its BioInsight platform, which brings analysis applications, AI models and curated biological data together in one place. Thaysen said the next era of life sciences will be powered by software, AI and differentiated data as well as sequencing.
When the AI business shows up in results
Asked by an RBC Capital Markets analyst when BioInsight becomes visible in the numbers, CFO Ankur Dhingra said it should begin to show somewhere in 2027. He named the Atlas, and a second generation expanding to five billion cells, as one of the first drivers. He tied this to the one to two points of growth management expects from new products and BioInsight in 2027.
Dhingra said instrument sales still account for over 90% of NovaSeq X placements, though interest in lease-type arrangements is rising among certain research customers.
The company raised its full-year guidance to revenue of $4.64 billion to $4.66 billion, and expects diluted earnings of $5.40 to $5.45 a share. Illumina's market value was $43.6 billion at Thursday's close.
Thaysen said he looks forward to sharing more about the AI strategy in coming quarters, and Illumina will give its 2027 guidance on the fourth-quarter call.
Sources
- Illumina: Q3 Earnings Snapshot – WTOP News — wtop.com
- Illumina Non-GAAP EPS of $1.44 beats by $0.08, revenue of $1.13B misses by $20M (NASDAQ:ILMN) | Seeking Alpha — seekingalpha.com
- Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026 – Company Announcement - FT.com — Financial Times
- Illumina: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Illumina: Q3 Earnings Snapshot | 11alive.com — Associated Press